Lancet (London, England) 2023 Jul 18
Safe and effective systemic therapy for early-stage non-small-cell lung cancer.
Related Questions
New answer by Radiation Oncologist at University of Florida Health Proton Therapy Institute (August 3, 2023)
Agree with the answers above and with some nuance. Completion of the phase III trials will be decisive in IO benefit in early-stage non-small cell lung cancer (ES-NSCLC). Howe...